Search Results for agency_names:"Health and Human Services Department"

The National Heart, Lung, and Blood Institute, part of the National Institutes of Health, has announced a closed meeting for the Heart, Lung, and Blood Initial Review Group to discuss grant applications. This virtual meeting, scheduled for February 20-21, 2025, from 9:00 a.m. to 12:00 p.m., will review applications that may involve confidential information, including trade secrets or personal data. Because of this sensitive content, the meeting will not be open to the public. For more information, Fungai Chanetsa, the Scientific Review Officer, can be contacted at the provided details.

The National Institute on Aging is holding a closed meeting on January 10, 2025, to review and evaluate grant applications related to bone regulation. The meeting will be conducted virtually from 10:00 a.m. to 5:00 p.m. The session is closed to the public because it will involve discussions of confidential information, like trade secrets or personal details in grant applications, which must remain private. Dr. Nijaguna Prasad is the contact person for the meeting, and inquiries can be directed to him via phone or email.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development has announced a closed meeting of its Initial Review Group for the Biobehavioral and Behavioral Sciences Study Section. The meeting is scheduled for March 25, 2025, from 9:00 a.m. to 5:00 p.m. It will take place virtually and is not open to the public to protect confidential information related to grant applications. Participants will review and evaluate these applications during the meeting.

The Food and Drug Administration (FDA) has announced its determination of the regulatory review period for the human drug BYLVAY. The FDA made this determination following a request from the U.S. Patent and Trademark Office for information related to patent term restoration. BYLVAY, approved for treating pruritis in patients aged 3 months and older with progressive familial intrahepatic cholestasis, underwent 1,868 days of regulatory review, including a testing phase of 1,625 days and an approval phase of 243 days. This notice invites anyone with information suggesting that these dates might be incorrect to submit their comments for consideration.

The Centers for Disease Control and Prevention (CDC) and the Health and Human Services Department announced a closed meeting of the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel scheduled for April 13-14, 2021. The meeting, which will be held via teleconference, aims to review and evaluate grant applications related to public health research in countries like Bangladesh, Thailand, Kenya, and others. The sessions are closed to the public to protect sensitive information, such as trade secrets and personal data about individuals involved in the grant applications. For more details, contact Dr. Hylan Shoob at the CDC.

The Office of Planning, Research, and Evaluation (OPRE) within the Administration for Children and Families (ACF) is seeking public comments on new report templates for the Healthy Marriage and Responsible Fatherhood (HMRF) programs. These templates are intended to help grant recipients efficiently report their evaluation findings as required by the ACF. The request is connected to the HMRF Local Evaluation Technical Assistance projects, which support the evaluation of programs aimed at improving family stability and healthy relationships. Public comments must be submitted by January 6, 2025, to be considered in OMB’s decision-making process.

The National Institute of Neurological Disorders and Stroke announced a change to the dates of the NST-2 Study Section meeting. Originally scheduled for April 3 and 4, 2025, the meeting will now take place on April 21 and 22, 2025, at the same times. This adjustment was published following a prior notice in the Federal Register. The meeting will be closed to the public.

The Food and Drug Administration (FDA) has made available a final guidance document titled "Notifying FDA of a Permanent Discontinuance or Interruption in Manufacturing of a Device Under Section 506J of the FD&C Act." This guidance updates a previous version and includes a list known as the 506J Device List, which outlines device product codes that manufacturers must notify the FDA about if they stop production. The document clarifies that manufacturers can also voluntarily notify the FDA of any supply chain issues, regardless of public health emergencies. This guidance aims to facilitate continuous device supply and prevent shortages.

The Centers for Disease Control and Prevention (CDC) submitted an information collection request for the "Assessment of Ill Worker Policies Study" to the Office of Management and Budget. This research, involving collaboration with various agencies and local health programs, aims to evaluate if an educational intervention can improve restaurant policies regarding sick workers. The study involves observing and interviewing restaurant managers across different locations to see if policy changes occur following the intervention. Feedback from participating partners helped refine this study, which was initially delayed due to the COVID-19 pandemic.

The National Institute on Aging will hold a closed meeting on February 19, 2025, focused on reviewing and evaluating grant applications related to Retromer Function and Alzheimer's Disease. The meeting will occur virtually from 10:00 a.m. to 3:00 p.m. The discussions will address confidential information, including trade secrets and personal details, which is why the meeting is closed to the public. Interested parties can contact Dr. Michael James Butler for more information.